| CreoSalus was originally founded as Thorn Bioscience LLC by Mrs. Laura Thorn in 1995. Its original and continuing mission is to develop novel peptide-based veterinary drugs for use in reproductive management, therapeutics, and vaccines of domestic animals. These products are a continuation of work initiated by Thornbrook Farm's New York Reproductive Research and Development Laboratory, an international leader in equine reproductive research in its own right and by virtue of its support of research at leading universities. In 1998, the ownership of the company was expanded to include approximately 70 individual investors. Together with Mrs. Torn, these investors represent the foundation of the company's current ownership.
In May of 2005, Thorn Bioscience acquired ACT Holdings and Thuramed Devices. ACT Holdings held, as its primary interest, the assets of Advanced ChemTech, a peptide building blocks, scale-up and custom synthesis company. Thuramed Devices held, as its primary assets, substantial intellectual property in cardiology, women's health and peptide synthesizer technology. In June of 2005, the parent company was renamed CreoSalus, Inc. which comes from the Latin "to create good health".
|
Search Product